as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹291.65
Change
+0.45 (0.15%)
Open
₹291.0
Prev. Close
₹291.2
Day High
₹305.0
Day Low
₹287.05
Volume Analysis
Traded
70,458
Delivered
28,716
Delivery %
40.76%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (3)
- •Low return on equity (2.18%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (42/100)
Opportunities (1)
- •Strong 3-year revenue growth (16.3%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹320.04 | ₹312.52 | ₹302.09 | ₹294.57 | ₹284.14 | ₹276.62 | ₹266.19 |
| Fibonacci | ₹312.52 | ₹305.66 | ₹301.43 | ₹294.57 | ₹287.71 | ₹283.48 | ₹276.62 |
| Camarilla | ₹296.59 | ₹294.94 | ₹293.3 | ₹294.57 | ₹290.0 | ₹288.36 | ₹286.71 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-18.36%
1 Week
-4.53%
1 Month
-6.58%
3 Months
+7.82%
6 Months
+12.87%
1 Year
-28.17%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹261.78
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
3.27%
Net margin 5.5% × asset turnover 0.45x × equity multiplier 1.32x
Company Overview
Sector
Chemicals
Market Cap
₹489 Cr
P/E (TTM)
34.2
ROE
2.18%
Book Value
₹387.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Shivalik Rasayan Limited scores weakly on TopFund's composite fundamentals check within the Chemicals sector, at 42/100. The strongest factor is Financial Strength (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (2.18%); promoter holding is falling. Strong 3-year revenue growth (16.3%).
TopFund Score — Fundamentals Quality
42/100 — WeakData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Stock is trading at 0.79 times its book value
- −Promoter holding has decreased over last quarter: -0.83%
- −Company has a low return on equity of 2.69% over last 3 years.
- −Dividend payout has been low at 5.73% of profits over last 3 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Shivalik Rasayan filed USFDA DMF for Avapritinib API; complete assessment completed.
Company received Regulation 29 disclosure from Ginnerup Capital ApS for warrant acquisition.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 67 | 70 | 71 | 75 | 82 | 85 | 69 | 89 | 94 | 82 | 103 | 96 | 101 |
| Expenses + | 57 | 61 | 62 | 65 | 71 | 72 | 64 | 78 | 82 | 72 | 90 | 85 | 86 |
| Operating Profit | 10 | 9 | 9 | 9 | 12 | 13 | 6 | 11 | 12 | 10 | 12 | 11 | 15 |
| OPM % | 14.41% | 12.62% | 13.04% | 12.57% | 14.26% | 15.61% | 8.3% | 12.29% | 12.83% | 12.58% | 12.09% | 11.6% | 14.75% |
| Other Income + | 1 | 2 | 1 | 1 | 0 | 2 | 6 | 1 | 0 | 1 | 2 | 1 | 0 |
| Interest | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 3 |
| Depreciation | 3 | 3 | 3 | 4 | 5 | 5 | 3 | 5 | 5 | 5 | 4 | 4 | 5 |
| Profit before tax | 5 | 6 | 5 | 5 | 5 | 8 | 6 | 4 | 5 | 4 | 8 | 6 | 7 |
| Tax % | 45.02% | 24.78% | 9.09% | 16.09% | 11.6% | 11.38% | 13.21% | 31.88% | 21.35% | 11.14% | 7.12% | 20.49% | 20.62% |
| Net Profit + | 3 | 4 | 5 | 4 | 4 | 7 | 5 | 3 | 4 | 4 | 7 | 5 | 5 |
| EPS in Rs | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 1 | 2 | 2 | 3 | 2 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 19 | 22 | 13 | 16 | 23 | 21 | -3 | 20 | 14 | -4 | 48 | 8 | 7 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 41 | 110 | 123 | 155 | 171 | 186 | 198 | 215 | 234 | 273 | 312 | 368 | 382 |
| Expenses + | 38 | 99 | 105 | 131 | 147 | 157 | 159 | 167 | 191 | 232 | 271 | 321 | 333 |
| Operating Profit | 3 | 10 | 18 | 24 | 24 | 29 | 38 | 47 | 43 | 41 | 41 | 47 | 49 |
| OPM % | 7.0% | 9.0% | 15.0% | 16.0% | 14.0% | 16.0% | 19.0% | 22.0% | 19.0% | 15.0% | 13.0% | 13.0% | 13.0% |
| Other Income + | 0 | 1 | 1 | 3 | 8 | 3 | 1 | 4 | 5 | 4 | 8 | 4 | 4 |
| Interest | 0 | 5 | 6 | 4 | 3 | 2 | 2 | 3 | 5 | 9 | 8 | 11 | 10 |
| Depreciation | 0 | 2 | 2 | 2 | 3 | 4 | 9 | 11 | 12 | 12 | 16 | 19 | 18 |
| Profit before tax | 3 | 5 | 11 | 20 | 26 | 27 | 29 | 37 | 32 | 23 | 25 | 21 | 24 |
| Tax % | 33.0% | 33.0% | 25.0% | 25.0% | 20.0% | 17.0% | 15.0% | 7.0% | 6.0% | 22.0% | 12.0% | 16.0% | — |
| Net Profit + | 2 | 3 | 8 | 15 | 21 | 22 | 25 | 34 | 30 | 18 | 22 | 18 | 21 |
| EPS in Rs | 2 | 4 | 10 | 14 | 10 | 10 | 13 | 18 | 14 | 8 | 11 | 8 | 9 |
| Dividend Payout % | 0.0% | 0.0% | 4.0% | 3.0% | 5.0% | 2.0% | 4.0% | 3.0% | 3.0% | 6.0% | 5.0% | 6.0% | — |
| Sales growth | — | 166 | 12 | 26 | 10 | 9 | 6 | 9 | 9 | 16 | 14 | 18 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 8 | 11 | 7 | 45 | 158 | 169 | 172 | 280 | 412 | 500 | 528 | 591 | 613 |
| Borrowings + | 0 | 31 | 32 | 22 | 20 | 10 | 29 | 38 | 58 | 76 | 105 | 123 | 107 |
| Other Liabilities + | 11 | 36 | 52 | 81 | 103 | 142 | 155 | 163 | 101 | 109 | 93 | 97 | 92 |
| Total Liabilities | 23 | 81 | 94 | 152 | 288 | 328 | 363 | 488 | 578 | 692 | 734 | 819 | 821 |
| Fixed Assets + | 7 | 27 | 27 | 40 | 41 | 52 | 210 | 221 | 218 | 214 | 337 | 335 | 333 |
| CWIP | 0 | 0 | 0 | 0 | 26 | 102 | 0 | 3 | 57 | 117 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 16 | 53 | 66 | 111 | 222 | 175 | 153 | 264 | 303 | 362 | 398 | 484 | 488 |
| Total Assets | 23 | 81 | 94 | 152 | 288 | 328 | 363 | 488 | 578 | 692 | 734 | 819 | 821 |
| Equity Capital | 3 | 3 | 3 | 4 | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 4 | 12 | 8 | -7 | -8 | 6 | 59 | 11 | -19 | -8 | -9 | -34 |
| Cash from Investing Activity + | 0 | -18 | -4 | -24 | -24 | -102 | -65 | -23 | -71 | -74 | -21 | -21 |
| Cash from Financing Activity + | 1 | 3 | -3 | 52 | 100 | 10 | 2 | 78 | 50 | 89 | 21 | 62 |
| Net Cash Flow | 4 | -3 | 2 | 21 | 69 | -86 | -4 | 66 | -40 | 7 | -10 | 6 |
| Free Cash Flow | 3 | 10 | 5 | -22 | -37 | -85 | -6 | -14 | -82 | -76 | -32 | -51 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 161 | 131 | 52 | -21 | -12 | 41 | 171 | 37 | -31 | -9 | -16 | -66 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 50.28% | 48.17% | 49.0% | 47.87% | 46.81% | 47.72% | 47.71% | 47.76% | 48.62% | 48.43% | 51.43% | 52.72% |
| Promoters | 47.95% | 47.95% | 47.95% | 47.95% | 47.95% | 47.37% | 47.37% | 47.37% | 47.37% | 47.37% | 47.37% | 46.54% |
| FII | 1.18% | 2.99% | 2.15% | 3.28% | 4.33% | 4.28% | 4.36% | 4.38% | 3.9% | 4.2% | 1.2% | 0.72% |
| DII | 0.59% | 0.88% | 0.88% | 0.88% | 0.88% | 0.64% | 0.56% | 0.48% | 0.12% | 0.0% | 0.02% | 0.01% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Chemicals — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Shivalik Rasayan Limited (this stock) | 489 | 34.2 | 0.79 | 2.18% |
| Primo Chemicals Limited | 484 | 43.9 | 1.2 | 3.82% |
| Aarti Surfactants Limited | 476 | 14.8 | 1.8 | 5.16% |
| Asahi Songwon Color Ltd | 460 | 9.65 | 1.51 | 7.14% |
| Best Agrolife Limited | 520 | 10.8 | 0.6 | 1.18% |
| Alufluoride Ltd. | 528 | 16.5 | 3.66 | 22.0% |
| Chemfab Alkalis Limited | 445 | — | 1.19 | -2.49% |
Which Mutual Funds Hold Shivalik Rasayan Limited?
Frequently Asked Questions about Shivalik Rasayan Limited
Shivalik Rasayan Limited (SHIVALIK) closed at ₹291.65 on NSE on 19 November 2026, up 0.45 (0.15%) from the previous close.
Shivalik Rasayan Limited trades on the NSE (National Stock Exchange of India) under the symbol SHIVALIK.
Shivalik Rasayan Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 34.2.
Shivalik Rasayan Limited has a dividend yield of 0.16%.
Shivalik Rasayan Limited's 52-week high is ₹438.0 and its 52-week low is ₹206.0.
Shivalik Rasayan Limited has a market capitalisation of ₹489 crore.
Shivalik Rasayan Limited has a TopFund Quality Score of 42/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Shivalik Rasayan Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.